Cancer Stem Cell News Volume 5.31 | Aug 10 2016

TOP STORY

An Activated Form of ADAM10 Is Tumor Selective and Regulates Cancer Stem-Like Cells and Tumor Growth

The authors report prevalence of an active form of ADAM10 in tumors compared with normal tissues, in mouse models and humans, identified by our conformation-specific antibody mAb 8C7. This active ADAM10 form marks cancer stem-like cells with active Notch signaling, known to mediate chemoresistance. [J Exp Med] Abstract

(Ranked by impact factor of the journal)

Rictor Plays a Pivotal Role in Maintaining Quiescence as Well as Stemness of Leukemia Stem Cells in MLL-Driven Leukemia

Scientists demonstrated that Rictor is essential for the maintenance of MLL-driven leukemia by preventing LSCs from exhaustion. [Leukemia] Abstract

Tissue Stiffness and Hypoxia Modulate the Integrin-Linked Kinase ILK to Control Breast Cancer Stem-Like Cells

Investigators report that stiff and hypoxic microenvironments promote the development of breast cancer stem-like cells through modulation of the integrin-linked kinase ILK. [Cancer Res] Abstract

Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-Catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia

Researchers aimed to examine the interplay between NF-κB and FOXM1/β-catenin, and the effect of its chemical intervention on chronic myelogenous leukemia stem cells. [Clin Cancer Res] Abstract

S100B Mediates Stemness of Ovarian Cancer Stem-Like Cells through Inhibiting p53

Scientists hypothesized that S100B might exert pro-tumor effects by regulating ovarian cancer stem-like cells (CSLCs) stemness, a key characteristic of CSLCs. [Stem Cells] Abstract

Fascin Is Critical for the Maintenance of Breast Cancer Stem Cell Pool Predominantly via the Activation of the Notch Self-Renewal Pathway

Investigators manipulated fascin expression in breast cancer cell lines and used several in vitro and in vivo approaches to examine the relationship between fascin expression and breast cancer stem cells. [Stem Cells] Abstract

Hypoxia-NOTCH1-SOX2 Signaling Is Important for Maintaining Cancer Stem Cells in Ovarian Cancer

Investigators identified SOX2 as a key transcription factor for cancer stem cells-like characteristics in the downstream of hypoxia-induced NOTCH signaling in epithelial ovarian cancer cells. [Oncotarget] Full Article

A Radiosensitizing Effect of RAD51 Inhibition in Glioblastoma Stem-Like Cells

Researchers analyzed the DNA damage response following ionizing radiation in 10 glioblastoma stem cells lines derived from patients. [BMC Cancer] Full Article

CCL21/CCR7 Axis Contributed to CD133⁺ Pancreatic Cancer Stem-Like Cell Metastasis via EMT and Erk/NF-κB Pathway

Scientists investigated the role of chemokine ligand 21(CCL21)/C-C chemokine receptor 7 (CCR7) in promoting epithelial-mesenchymal transition (EMT) and metastasis of cluster of differentiation 133⁺ (CD133⁺) pancreatic cancer stem-like cells. [PLoS One] Full Article

Laminins and Cancer Stem Cells: Partners in Crime?

Laminins participate in key cellular events for tumor angiogenesis, cell invasion and metastasis development, including the regulation of epithelial-mesenchymal transition and basement membrane remodeling, which are tightly associated with the phenotypic characteristics of stem-like cells, particularly in the context of cancer. [Semin Cancer Biol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Plasticell and National University of Ireland Initiate Cancer Stem Cell Collaboration

Plasticell announced the signing of a collaboration agreement with the National University of Ireland, Galway focused on methods of eradicating cancer stem cells. [Plasticell] Press Release

Damon Runyon Cancer Research Foundation Grants Fellowships to 17 Top Young Scientists

The Damon Runyon Cancer Research Foundation named 17 new Damon Runyon Fellows at its spring Fellowship Award Committee review. [Damon Runyon Cancer Research Foundation] Press Release

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401

DNAtrix announced the award of a $2 million research grant from the FDA’s Office of Orphan Products Development to support its Phase II clinical trial evaluating DNX-2401 with the checkpoint inhibitor pembrolizumab for patients with recurrent glioblastoma. [DNAtrix] Press Release

Beyond CRISPR: A Guide to the Many Other Ways to Edit a Genome

The zeal with which researchers jumped on a possible new gene-editing system called NgAgo earlier this year reveals an undercurrent of frustration with CRISPR–Cas9 — and a drive to find alternatives. [Nature News] Editorial

US Agency Lifts Ban on Funding Human–Animal Hybrids

Researchers in the United States will soon be able to resume creating chimera-based projects. [Nature News] Editorial

The FDA Is Prohibited from Going Germline

A potentially renewable provision of the Consolidated Appropriation Act of 2016 forestalling the prospect of human germline modification was signed into law on December 18th, 2015. The provision has since been incorporated again into the House and Senate appropriation bills for the fiscal year. [ScienceInsider] Editorial

NEW Keystone Symposium: Inflammation-Driven Cancer: Mechanisms to Therapy
February 5-9, 2017
Keystone, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Metastatic Breast Cancer (Purdue Center for Cancer Research)

NEW Core Staff Scientist (Moffitt Cancer Center)

Principal Investigator – Clinical Geneticist in Pediatric Leukemia (Children´s Cancer Research Institute, St. Anna Kinderkrebsforschung)

Bioinformatician – Bioinformatics Data Analysis (Children´s Cancer Research Institute, St. Anna Kinderkrebsforschung)

Scientific Coordinator – Scientific Project Management (The Swiss Federal Institute of Technology in Zurich)

Senior Research Assistant – Differentiation and Survival of Leukemia Stem Cells (The University of Texas MD Anderson Cancer Center)

Tenure Track Faculty – Biological Sciences Scholars Program (University of Michigan)

Postdoctoral Fellow – Cancer Stem Cell Biology (Cleveland Clinic Lerner Research Institute)

Postdoctoral Research Assistant – Epigenetics and Immune-Oncology (University of Oxford)

Postdoctoral Fellow – Synthetic Cancer Biology (Beth Israel Deaconess Medical Center and Harvard Medical School)

Postdoctoral Fellow – Tumor Biology in Multiple Myeloma (Lerner Research Institute, Cleveland Clinic)

Institute Associate Scientist III – Target Biology (MD Anderson Cancer Center)

Postdoctoral Fellowship – Wnt Pathway in Sarcoma Pathogenesis (University of Miami Health System)

Senior Cancer Analyst – 100,000 Genomes Project (Queen Mary University of London)

Postdoctoral Fellow – Cancer Stem Cell Biology (Cleveland Clinic Lerner Research Institute)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.